Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Ocular Therapeutix Inc (NASDAQ: OCUL) was $7.91 for the day, up 3.94% from the previous closing price of $7.61. In other words, the price has increased by $3.94 from its previous closing price. On the day, 1.02 million shares were traded. OCUL stock price reached its highest trading level at $8.07 during the session, while it also had its lowest trading level at $7.62.
Ratios:
Our analysis of OCUL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.59 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.
On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on March 11, 2025, with a $15 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 24 ’25 when Dugel Pravin sold 21,475 shares for $6.87 per share. The transaction valued at 147,533 led to the insider holds 3,520,318 shares of the business.
Heier Jeffrey S. sold 3,061 shares of OCUL for $21,029 on Feb 24 ’25. The Chief Scientific Officer now owns 265,998 shares after completing the transaction at $6.87 per share. On Feb 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,009 shares for $6.87 each. As a result, the insider received 20,672 and left with 210,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1257863936 and an Enterprise Value of 941705984. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.74 while its Price-to-Book (P/B) ratio in mrq is 3.96. Its current Enterprise Value per Revenue stands at 14.778 whereas that against EBITDA is -5.553.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.42, which has changed by 0.70290637 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is 8.78%, while the 200-Day Moving Average is calculated to be -6.83%.
Shares Statistics:
OCUL traded an average of 1.49M shares per day over the past three months and 1704910 shares per day over the past ten days. A total of 157.75M shares are outstanding, with a floating share count of 133.91M. Insiders hold about 15.79% of the company’s shares, while institutions hold 72.75% stake in the company. Shares short for OCUL as of 1743379200 were 12586674 with a Short Ratio of 8.47, compared to 1740700800 on 12048382. Therefore, it implies a Short% of Shares Outstanding of 12586674 and a Short% of Float of 7.95.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
